| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
42,345,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vera Therapeutics is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Co.'s primary product candidate, atacicept, a self-administered fusion protein that blocks both blisibimod and APRIL, is being evaluated for the treatment of immunoglobulin A nephropathy in a global, randomized, double-blind, placebo-controlled clinical trial. Co. has obtained worldwide, exclusive development and commercial rights from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for MAU868, a potentially monoclonal antibody to treat BK viremia infections.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
161,290 |
161,290 |
614,507 |
4,957,633 |
| Total Buy Value |
$4,999,990 |
$4,999,990 |
$11,881,994 |
$42,392,668 |
| Total People Bought |
1 |
1 |
3 |
8 |
| Total Buy Transactions |
1 |
1 |
3 |
27 |
| Total Shares Sold |
958,650 |
2,008,650 |
2,016,840 |
2,287,944 |
| Total Sell Value |
$39,017,864 |
$57,917,864 |
$58,054,276 |
$63,362,460 |
| Total People Sold |
3 |
4 |
7 |
8 |
| Total Sell Transactions |
6 |
7 |
10 |
41 |
| End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
• – – |
2024-04-10 |
4 |
S |
$40.00 |
$228,560 |
D/D |
(5,714) |
53,171 |
|
- |
|
| Grant Sean |
CHIEF FINANCIAL OFFICER |
• – – |
2024-04-03 |
4 |
S |
$38.20 |
$735,205 |
I/I |
(18,649) |
5,000 |
|
- |
|
| Grant Sean |
CHIEF FINANCIAL OFFICER |
• – – |
2024-04-03 |
4 |
S |
$38.13 |
$3,954,516 |
D/D |
(99,828) |
66,337 |
|
- |
|
| Grant Sean |
CHIEF FINANCIAL OFFICER |
• – – |
2024-04-03 |
4 |
OE |
$14.87 |
$1,484,442 |
D/D |
99,828 |
166,165 |
|
- |
|
| Katabi Maha |
Director |
– • – |
2024-03-25 |
4 |
S |
$40.50 |
$13,770,000 |
I/I |
(340,000) |
2,793,987 |
|
- |
|
| Katabi Maha |
Director |
– • – |
2024-03-22 |
4 |
S |
$40.51 |
$16,748,860 |
I/I |
(413,450) |
3,133,987 |
|
- |
|
| Katabi Maha |
Director |
– • – |
2024-03-21 |
4 |
S |
$43.00 |
$3,580,723 |
I/I |
(81,009) |
3,547,437 |
|
- |
|
| Katabi Maha |
Director |
– • – |
2024-01-30 |
4 |
B |
$31.00 |
$4,999,990 |
I/I |
161,290 |
3,628,446 |
2.1 |
- |
|
| Grant Sean |
CHIEF FINANCIAL OFFICER |
• – – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
78,683 |
|
- |
|
| Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
• – – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
21,875 |
57,054 |
|
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
78,750 |
335,627 |
|
- |
|
| Commodore Capital Lp |
10% Owner |
– – • |
2024-01-10 |
4 |
S |
$18.00 |
$18,900,000 |
I/I |
(1,050,000) |
4,400,000 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2023-12-29 |
4 |
OE |
$2.32 |
$38,854 |
D/D |
13,516 |
256,877 |
|
- |
|
| Grant Sean |
CHIEF FINANCIAL OFFICER |
• – – |
2023-12-20 |
4 |
GD |
$0.00 |
$0 |
I/I |
636 |
18,021 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2023-08-21 |
4 |
AS |
$16.66 |
$86,779 |
D/D |
(5,210) |
243,361 |
|
- |
|
| Lin Celia |
Chief Medical Officer |
• – – |
2023-08-21 |
4 |
AS |
$16.65 |
$24,816 |
D/D |
(1,490) |
11,010 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2023-08-21 |
4 |
AS |
$16.66 |
$24,817 |
D/D |
(1,490) |
26,962 |
|
- |
|
| Grant Sean |
CHIEF FINANCIAL OFFICER |
• – – |
2023-07-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,620 |
1,620 |
|
- |
|
| Grant Sean |
CHIEF FINANCIAL OFFICER |
• – – |
2023-07-24 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,620 |
18,657 |
|
- |
|
| Young Joseph R |
SVP, Finance, Chief Acct Offcr |
• – – |
2023-07-05 |
4 |
OE |
$3.94 |
$39,396 |
D/D |
10,000 |
32,679 |
|
- |
|
| Grant Sean |
Chief Financial Officer |
• – – |
2023-06-23 |
4 |
B |
$16.60 |
$83,000 |
I/I |
5,000 |
5,992 |
1.99 |
- |
|
| Commodore Capital Lp |
10% Owner |
– – • |
2023-06-20 |
4 |
B |
$15.17 |
$6,799,004 |
I/I |
448,217 |
5,450,000 |
1.5 |
- |
|
| Commodore Capital Lp |
10% Owner |
– – • |
2023-06-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,001,783 |
|
- |
|
| Seidenberg Beth C |
Director |
– • – |
2023-03-28 |
4 |
B |
$7.24 |
$173,192 |
I/I |
23,908 |
1,946,995 |
2.1 |
- |
|
| Seidenberg Beth C |
Director |
– • – |
2023-03-27 |
4 |
B |
$7.24 |
$11,830 |
I/I |
1,633 |
1,923,087 |
2.1 |
- |
|
134 Records found
|
|
Page 1 of 6 |
|
|
